Generate Biomedicines vs GE HealthCare

Side-by-side comparison of AI visibility scores, market position, and capabilities

GE HealthCare leads in AI visibility (93 vs 57)
Generate Biomedicines logo

Generate Biomedicines

ChallengerHealthcare Tech

AI Drug Discovery & Generative Biology

Generative biology biotech using AI to design protein therapeutics. IPO'd on Nasdaq (GENB) Feb 2026, raising $400M. Lead drug GB-0895 in Phase 3 for severe asthma.

AI VisibilityBeta
Overall Score
C57
Category Rank
#1 of 1
AI Consensus
56%
Trend
up
Per Platform
ChatGPT
63
Perplexity
56
Gemini
50

About

Generate Biomedicines is a clinical-stage biotech founded in 2018 by Flagship Pioneering, headquartered in Somerville, Massachusetts. The company pioneers generative biology, using ML and large-scale experimental systems to design protein therapeutics. Its platform combines diffusion and graph-based AI models with high-throughput biohardware. The pipeline spans immunology, oncology, and infectious diseases.

Full profile
GE HealthCare logo

GE HealthCare

LeaderHealthcare Tech

Enterprise

Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers.

AI VisibilityBeta
Overall Score
A93
Category Rank
#183 of 290
AI Consensus
61%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
95
Gemini
85

About

GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer.

Full profile

AI Visibility Head-to-Head

57
Overall Score
93
#1
Category Rank
#183
56
AI Consensus
61
up
Trend
stable
63
ChatGPT
99
56
Perplexity
95
50
Gemini
85
68
Claude
84
65
Grok
89

Key Details

Category
AI Drug Discovery & Generative Biology
Enterprise
Tier
Challenger
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Generate Biomedicines
AI Drug Discovery & Generative Biology
Generate Biomedicines is classified as company. GE HealthCare is classified as company (part of GE Aerospace).

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.